Microalbuminuria has emerged as an important predictor of cardiovascular risk. Several studies showed that microalbuminuria is associated with an increased risk of all-cause and cardiovascular mortality among elderly 1 and diabetic people, 2 as well as in the general population. 3 Although microalbuminuria is a common finding in the general population, even after exclusion of diabetic and hypertensive subjects, 4 little is known about the predictors of albuminuria, particularly in the normal population. Age, male sex, blood pressure, dyslipidaemia, obesity, smoking and history of cardiovascular disease have all been described, 4 but there is still great interindividual variability among the risk conferred by these risk factors on albuminuria, highlighting the possible role of genetic components.
Currently, a great amount of evidence suggests that renin-angiotensin-aldosterone system (RAS) is one of the key hazardous systems involved in the progression of chronic nephropathy and ACE inhibitors and angiotensin II receptor blockers are the main treatment available. In this context, RAS gene variants could be good candidates to explain microalbuminuria variability seen in the general population. Indeed, previous studies have suggested that the deletion (D) polymorphism of ACE gene is associated with a higher risk of microalbuminuria among diabetic 5 and hypertensive subjects. 6, 7 Data regarding the T235 variant of the angiotensinogen gene (AGT) are more scarce and conflicting. 7 However, few studies were population-based and extrapolations to the general population may not be straightforward.
In this study, we aimed to examine the relationship between blood pressure and ACE and angiotensinogen functional polymorphisms on the risk of microalbuminuria in a sample derived from the general population.
A cross-sectional study of cardiovascular disease risk factors was performed in the urban population of Vitoria, Brazil, following the general guidelines of the WHO-MONICA project. 8 Initially, from an eligible population of 137 330, 2044 people aged 25-64 years were randomly selected and invited to participate the study. The study protocol was approved by the Institutional Review Board of the Espirito Santo Federal University and all participants signed an informed consent. From this sample, 1577 attended to a health check and answered a short health and lifestyle questionnaire. Height, weight and blood pressure measurements were performed and blood and urine samples were collected after a 12-h fasting period. Blood pressure was measured by trained technicians using a standard mercury sphygmomanometer on the left arm after a 5-min rest with the subject in the sitting position. The mean of three measures taken by different technicians with a 10-min interval was used. Diabetes was defined as a fasting glycaemia equal or higher than 126 mg/dl. Subjects were submitted to a racial classification, according to a validated questionnaire for the Brazilian population. 9 Microalbuminuria was performed by a semiquantitative assay using a commercial kit (Micral-Test II, Boehringer Mannheiem) and tests with an albumin concentration higher than 4 mg/dl were considered positive. The ACE gene I/D polymorphism was determined through a 3-primer system and the M235T variant of the AGT gene by a standard PCR detection method. Urinary sampling and ACE and angiotensinogen polymorphisms could be ascertained for 1015 individuals and this was the final sample used in the analyses.
All analyses were carried out using the Statistical Package StatView for Windows ver. 5. Subjects were classified as carriers or not of the D and T alleles. Student's t-test and w 2 test were used for univariate comparisons on continuous and categorical variables, respectively. We performed multiple logistic regression of quartiles of systolic and diastolic blood pressure on risk of microalbuminuria stratified by genotype groups, adjusting for the effect of age, sex, diabetes mellitus, BMI and ethnicity. Finally, logistic regression models were also used for calculating interaction terms between ACE and AGT genotype and systolic and diastolic blood pressure. Tests were two-sided and considered significant when P-values were less than 0.05. ACE and AGT genotype distribution in this population were previously described. 8 The DD þ DI participants did not differ from the II participants regarding demographic characteristics except for male sex (43.2 (DD þ DI) Â 30.8 (II), P ¼ 0.004) and Caucasian ethnicity (32.6 (DD þ DI) Â 22.4 (II), P ¼ 0.04). When compared to the MM group, T carriers had higher BMI (26.5 Â 25.5, P ¼ 0.009), lower relative frequencies of male sex (38.8 Â 51.8, Po0.001) and Caucasian ethnicity (27.6 Â 45.4, Po0.001) frequencies and, more importantly, higher systolic blood pressure (129.6 Â 123.7, Po0.001).
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In Table 1 , we show the results of logistic regression models using quartiles of systolic and diastolic blood pressure. It is important to highlight that only the last quartile of both diastolic and systolic blood pressure comprises participants with blood pressure levels above 140 Â 90 mmHg. After adjusting for the effect of age, sex, diabetes mellitus, BMI and ethnicity, the DD þ DI and TT þ TM participants showed an increased risk of microalbuminuria, an effect not seen in the II and MM groups. It is interesting to note that a linear trend was observed along increasing quartiles of blood pressure in DD þ DI and TT þ TM individuals.
Logistic regression models were also used to calculate interaction terms between ACE and AGT polymorphism and systolic and diastolic blood pressure, after adjusting for the effect of age, sex, diabetes mellitus, BMI and race. A significant interaction term was found only for ACE polymorphism and systolic blood pressure (OR 1.04, P ¼ 0.03).
Our results suggest that ACE and AGT functional genetic variants modulate the risk of microalbuminuria conferred by increased blood pressure levels. When participants were analysed according to quartiles of systolic and diastolic blood pressure, only those carrying a D or a T allele showed a linear trend of increasing microalbuminuria risk with higher blood pressure levels, even after adjustments for other covariates. A significant interaction term between ACE polymorphism and systolic blood pressure was found, suggesting that D allele is a risk factor for microalbuminuria in the general population.
The method was used to measure microalbuminuria has good accuracy (sensibility and specificity of 93% 10 ) and have been used for epidemiological purposes. 11, 12 It might be argued that because carriers of T allele tend to have a higher systolic blood pressure, this effect could confound the relationship between blood pressure and microalbuminuria risk. However, the mean systolic blood pressure within each quartile of systolic blood pressure was not significantly different between TT þ TM and MM individuals.
An interaction between blood pressure and ACE/ AGT polymorphisms seems biologically plausible since subjects carrying the D or T alleles tend to have higher angiotensin-II concentration. Thus, D or T carriers might be particularly susceptible to the harmful effects of blood pressure on glomerular haemodynamics, predisposing to microalbuminuria. It also can be speculated that RAS inhibition would be more beneficial amongst D and T allele carriers, What is known about topic: K Microalbuminuria is an important clinical tool to detect cardiovascular susceptibility and risk K Age, male sex, blood pressure, dyslipidaemia, obesity, smoking and history of cardiovascular disease have all been described as predictors of microalbuminuria, but there is still great interindividual variability among the risk conferred by these risk factors on albuminuria, highlighting the possible role of genetic components K Knowledge of both clinical and genetic determinants of microalbuminuria will lead to the development of more specific preventive measures
What this study adds: K ACE and AGT functional genetic variants modulate the risk of microalbuminuria conferred by increased blood pressure levels K Increased levels of systolic blood pressure were only predictive of the risk of microalbuminuria in our population in individuals carriers of the ACE D or the AGT T allele but whether different pharmacological responses occur in different genotype groups is a hypothesis that remains to be tested. In conclusion, microalbuminuria became an important clinical tool to detect cardiovascular susceptibility and risk. It seems to predict mortality and renal disease risk even among nondiabetic nonhypertensive people. Knowledge of both clinical and genetic determinants of microalbuminuria will lead to the development of more specific preventive measures.
